Home › NDC Lookup › RxCUI directory › RxCUI 485423

24 HR darifenacin 7.5 MG Extended Release Oral Tablet — RxCUI 485423

RxNorm drug concept · Semantic clinical drug
RxCUI 485423 Semantic clinical drug · SCD ● Current RxNorm concept 17 FDA products 52 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI485423
Official name24 HR darifenacin 7.5 MG Extended Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdarifenacin 7.5 MG (as darifenacin HBr 8.923 MG) 24 HR Extended Release Oral Tablet; darifenacin 7.5 MG 24HR Extended Release Oral Tablet
FDA products mapped17
Package NDCs mapped52
Reported Medicaid activity (SDUD)1,666 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Darifenacin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Your bladder has receptors called M3 receptors that trigger the muscle to squeeze. With overactive bladder, those squeezes happen too often or too forcefully. Darifenacin blocks th...
  • What exactly is darifenacin doing to help my bladder?
  • No — this one really matters. Darifenacin is an extended-release tablet, which means it's specially designed to release the medicine slowly over the day. If you chew, crush, or spl...
  • Can I cut or crush the tablet if it's hard to swallow?
📖 Read our full Darifenacin guide →

🕸️ Concept Web — How 24 HR darifenacin 7.5 MG Extended Release Oral T... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR darifenacin 7.5 MG Extended Release Oral Tablet RxCUI 485423

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Darifenacin 136198
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Enablex 397392
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Darifenacin Extended Release Oral Tablet 485420
    • Darifenacin Oral Product 1157181
    • Darifenacin Pill 1157182
    • Darifenacin Extended Release Oral Tablet [Enablex] 543020
    • Enablex Oral Product 1175954
    • Enablex Pill 1175955
    • Extended Release Oral Tablet 316945
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Darifenacin 7.5 MG 485422
    • 24 HR darifenacin 7.5 MG Extended Release Oral Tablet [Enablex] 543027
    • Darifenacin 7.5 MG [Enablex] 543026

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Darifenacin 7.5 MG SCDC · 485422
  • Darifenacin Extended Release Oral Tablet SCDF · 485420
  • Darifenacin Oral Product SCDG · 1157181
  • Darifenacin Pill SCDG · 1157182

Brand-Name Concepts

  • 24 HR darifenacin 7.5 MG Extended Release Oral Tablet [Enablex] SBD · 543027
  • Darifenacin 7.5 MG [Enablex] SBDC · 543026
  • Darifenacin Extended Release Oral Tablet [Enablex] SBDF · 543020
  • Enablex Oral Product SBDG · 1175954
  • Enablex Pill SBDG · 1175955
  • Enablex BN · 397392

📦 FDA Products & Package NDCs

17 products · 52 package NDCs
52 package NDCs map to RxCUI 485423 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
69097-0432-15 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (69097-432-15) Darifenacin Cipla USA Inc. 2016-09-01
72162-2570-03 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (72162-2570-3) Darifenacin Bryant Ranch Prepack 2025-11-17
Observed labelers: Alembic Pharmaceuticals Inc. (8) · Alembic Pharmaceuticals Limited (8) · Aurobindo Pharma Limited (8) · Cipla USA Inc. (6) · Macleods Pharmaceuticals Limited (6) · Torrent Pharmaceuticals Limited (6) · +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.